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Abstract
Although traditional Chinese medicine has benefitted one fifth of the world's population in treating
a plethora of diseases, its acceptance as a real therapeutic option by the West is only now emerging.
In light of a new wave of recognition being given to traditional Chinese medicine by health
professionals and regulatory bodies in the West, an understanding of their molecular basis and
highlighting potential future applications of a proven group of traditional Chinese medicine in the
treatment of a variety of cancers is crucial – this is where their calling holds much hope and promise
in both animal and human trials. Furthermore, the rationale for combining conventional agents and
modern biotechnological approaches to the delivery of traditional Chinese medicine is an avenue
set to revolutionize the future practice of cancer medicine – and this may well bring on a new dawn
of therapeutic strategies where East truly meets West.
Introduction
Reports of therapeutic success with traditional Chinese
medicine (TCM) have until very recently been met with
much scepticism and pessimism by the West, due in-part
to the sheer lack of available credible and rigorous clinical
data and at claims that a given TCM can remedy common
ailments and be just as efficacious in eliminating life
threatening diseases, such as cancer. The tide is now
beginning to turn on this negative outlook, aided by the
ever-increasing migration of people and along with them
knowledge (based upon ancestral cultural influences)
from two of the world's fasting growing populations,
China and India, to the West [1]. This translation to the
West of ancient complementary and alternative medicine
formularies and their ever-increasing integrative role in
the armoury against cancer means that their presence and
place in modern medicine can no longer be overlooked,
by regulatory authorities and clinicians alike, as being
merely anecdotal.
The age-old holistic approach employed by Chinese prac-
titioners proposes that a multitude of events are key to
returning a patient to a healthy state; where cancer therapy
is concerned these primarily include an interplay between
the induction of apoptosis/cell-cycle arrest, inhibition of
angiogenesis, overcoming multidrug resistance (MDR),
and boosting the immune system (Figure 1). Following an
extensive review of the literature we describe the detailed
molecular basis of a proven group of TCM, and highlight
reported synergies when administered alongside so-called
'conventional therapies' in tumour cell regulation and in
bringing about homeostasis.
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The many physiological growth control mechanisms that
regulate cell proliferation and tissue homeostasis are
linked to apoptosis and it follows that resistance devel-
oped to this 'programmed cell death' can be directly linked
to prolonged tumour cell survival and resistance to ther-
apy [2,3]. The processes resulting in apoptosis are medi-
ated by extrinsic (via  death receptors) or intrinsic (via
mitochondrial) pathways and although their paths are
not mutually exclusive, evidence suggests the latter cer-
tainly predominates where TCM is concerned [4]. Here we
look in some detail at two of the primary mechanisms –
'apoptosis' and 'angiogenesis' in the context of TCM, pro-
posed to be key avenues responsible for imparting thera-
peutic efficacy against a wide range of cancers.
Molecular basis of TCM – Apoptosis
Apoptosis is guided by a range of complex multi-step,
multi-pathway programs that eventuate in the breakdown
of cellular DNA leading to cell death [5]. And by far the
most emphasized and reported endpoint in TCM trials to-
date have been those of cell cycle arrest and apoptosis
[6,7]. The cascade of intracellular events triggering cell
death have been identified to involve activation or sup-
pression of a number of key receptors, genes and enzymes
[8]. The mitochondria, a cell's energy source, is recognized
as playing a central role in the sustained survival of cells
and many of the triggers to apoptosis are known to act
here, either directly or indirectly [9,10].
Apoptosis by the 'Caspase' effect
Of the pro-apoptotic enzymes implicated in TCM activity
the family of cysteine proteases, commonly termed 'cas-
pases' are key players with their role and function exten-
sively reviewed elsewhere [2,3,10]. Briefly, caspases are
divided into two broad groups, the 'initiators' and the
'executioners' and once activated they go on to activate
other pro-caspases that trigger apoptosis. The primary role
of 'initiator' caspases (caspase-8, -9 & -10) is the process-
ing and activation of both pro-enzymes (procaspase-8, -9
& -10) and 'executioner' caspases (mainly caspase-3, -6, &
-7) [2]. Pro-caspases are inactive forms of their cousins,
the caspases, and any processing of these pro-enzymes is
regarded as a reliable marker for caspase activation, and so
apoptosis. It is the result of 'executioner' caspases cleaving
each other that triggers an amplifying proteolytic cascade,
effecting cleavage/degradation of cellular substrates –
these aptly named 'death' substrates are responsible for
signalling biochemical and morphological changes that
eventuate in cell death [11].
Apoptosis by NF-Kb
Cellular stress is invoked by an imbalance in a cell's redox
state. Nuclear factor-κB (NF-κB) is a key regulatory mole-
cule, activated when a cell experiences oxidative stress
[12]. It is well-documented that tumour necrosis factor-α
(TNF-α) and the closely related tumour necrosis factor-
related apoptosis ligand (TRAIL) along with lipopolysac-
charides, interleukins (IL) and UV or IR radiation all
impart cellular stress that triggers the NF-κB cascade
[13,14]. NF-κB ordinarily resides in the cytosol of non-
stressed cells, non-covalently bound to the family of
inhibitory-κB (IκB) proteins which function to mask the
nuclear localization signal (NLS) present on NF-κB. When
the redox balance of the cell is perturbed by extracellular
stimuli, IκBs are rapidly degraded exposing the NLS. The
consequence is transfer of NF-κB to the nucleus where it
regulates gene expression, the products of which are
directly involved in tumorigenesis [15,16].
Apoptosis by TCM
Numerous studies have been aimed at deciphering the
precise molecular basis for a variety of TCM and those
most noteworthy are discussed below.
The root of Scutellaria Baicalensis (Figure 2), commonly
referred to as 'Baikal skullcap', 'Huang qin' or the 'Golden
Root', is probably one of the most widely used herbs in
TCM preparations with its flavonoid-rich elements con-
sidered to impart anti-inflammatory, anti-viral, anti-bac-
terial and anti-neoplastic activity [17-20].
It is also one of the most widely studied by researchers,
being used either alone or more often in combination
with other TCM for a range of cancers (in vitro and in vivo),
namely of the prostate, breast, lung, liver and ovaries
[6,21-23]. The roots chief therapeutic ingredient is baica-
lin, although it is converted to baicalein by intestinal gut
flora with this latter bioactive firmly considered to be the
primary active constituent responsible for its pro-apop-
totic and anti-proliferative effects [21]. Extensive studies
reveal that other flavonoids present within the herb e.g.
neobaicalein, wogonin and wogonoside are also at work
and that their co-synergies most likely contribute to the
observed efficacy [24]. The principle mechanism of action
of Scutellaria Baicalensi is via the inhibition of eicosanoid
synthesis – being important mediators of pro-inflamma-
The complex interplay between the primary mechanisms of  TCM Figure 1
The complex interplay between the primary mecha-
nisms of TCM.
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tory (cyclooxygenase-2 (Cox-2)) and tumour cell prolifer-
atory (lipoxygenase) markers [25]. Simultaneous
inhibition of Cox-2 and 12-lipooxygenase has been
shown to result in both reduced inflammation and tum-
origenesis [25,26]. The role of baicalein against cell prolif-
eration in PC-3 and DU145 prostate cancer cell lines is
that of cell cycle arrest (at G0-G1) while also inducing
apoptosis – confirmed via detection of caspase-3, at con-
centrations typical for administration to humans [27].
Further evidence of TCM acting via caspase activation and
NF-κB also exists with Takrisodokyeum (TRSDY) – com-
prising 12 herbs in various proportions [28]. Caspase-3
activity assays conducted by Kwon et al on promyelocytic
leukeamic cells (HL-60) cells pre-treated with TRSDY
revealed that apoptotic cell death was indeed caspase-3
induced [27]. Its activation resulting in classical apoptotic
signs including DNA fragmentation, chromatin conden-
sation and plasma membrane blebbing [29,30]. Introduc-
tion of a caspase-3 inhibitor resulted in no detectable
caspase-3 production and the downfield cleavage of cellu-
lar death substrates was also absent. It was further identi-
fied that oxidative stress by way of hydrogen peroxide
generation was a co-contributor to apoptosis in the same
population of cells. In an attempt to elucidate which of
caspase-3 or hydrogen peroxide was generated first, cells
were pre-treated with an antioxidant and scavenger,
quenching any oxidative agent. Levels of caspase-3 were
found to be negligible in this case, strengthening the
hypothesis that caspase-3 activation does not take place in
these cells without prior oxidative stress [31,32]. Whether
intracellular events leading to apoptosis follow this
sequence of events in other cancer cell lines using this or
other TCM is yet to be determined although parallel stud-
ies using other TCM do concur that activity is via selective
members of the caspase family, namely caspase-3 [33-36].
TRAIL has received considerable attention by researchers
since the discovery that most cancer cells are sensitive to
its apoptotic effect but that normal cells confer resistance
to it [37]. The potential of TRAIL as a realistic future ther-
apy against cancer was further encouraged by the discov-
ery that conventional therapy, namely chemotherapy or γ-
irradiation can sensitize cells previously resistant to TRAIL
[38-40]. The bioactive Triptolide (PG490) – extracted
from the TCM Tripterygium wilfordii has been studied
extensively for anti-inflammatory and immunosuppres-
sive activity, being shown to sensitize various types of
tumour cells to apoptosis induced by TRAIL, TNF-α and
chemotherapy [41-44]. A study conducted by Frese et al
evaluating PG490 suggests that it sensitizes previously
resistant Calu-1 lung cancer cell lines to TRAIL-induced
apoptosis while sparing normal human bronchial epithe-
lial cells [42]. PG490-mediated sensitization of the cells to
TRAIL requires activation of a family of extracellular-regu-
lated protein kinases (ERK's), namely ERK-1. Located in
the intracellular environment ERK-1 is thought to be the
crucial link bridging the process that follows death recep-
tor activation and precedes caspase activation. TRAIL, act-
ing via death receptors (TRAIL-R1 & R2) forms a death-
inducing signalling complex (DISC); this then recruits an
'initiator', caspase-8, which begins a cascade of protease
activation enlisting the 'executioner' – caspase-3, promot-
ing cleavage of death substrates with the end-point being
cell death. [45-47]. Carter et al confirmed the role of
PG490 in apoptosis and went further to highlight that
mitochondria, and not the death receptor, predominate in
PG490 activity in mouse embryonic fibroblasts, due to
caspase-9 activation [48]. This contradicted the findings
of Frese et al where caspase-8 was found to be the key pro-
enzyme in triggering apoptosis highlighting that mecha-
nistic variability indeed exists with TCM as would be
expected, thus caution must be taken when making any
broad claims relating to their precise mechanism of action
[42]. Synergistic induction of apoptosis has also been
observed when chemotherapeutic agents are employed
together with PG490, further corroborating the case for
TCM use with conventional anticancer agents [48].
All cancer cells possess an elevated apoptotic threshold
and although the therapeutic interventions of chemother-
apy and γ-irradiation are crucial they are commonly
plagued with resistance, resulting in a cycle of remission
and relapse. The ever-rising incidence of resistance to
chemotherapy suggests an increase in this apoptotic
threshold and so the challenge is whether it can be
reduced sufficiently to break the cycle at the point of
remission. Advances made in recognizing and activating
the key molecules involved in apoptotic pathways are cer-
tainly very encouraging from the perspective of eradicat-
ing a tumour although resistance to these interventions
are also emerging [49]. The growing acceptance of TCM as
a real adjunct therapy makes it an invaluable tool in the
fight against many cancers and it holds much promise
especially in cases where resistance to therapy is prevalent.
Plant (A) and root (B) of Scutellaria Baicalensis ('golden root')  where root scale is shown as 1 cm Figure 2
Plant (A) and root (B) of Scutellaria Baicalensis 
('golden root') where root scale is shown as 1 cm.
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Molecular basis of TCM – Angiogenesis
Angiogenesis – the creation of a healthy vascularised net-
work by a tumour is a key underlying process in the induc-
tion and establishment of cancer [50]. It, like apoptosis,
involves multi-step biochemical interactions that require
activation of cell-signalling pathways, supply of nutrients
and a host immune response. A range of TCM such as the
Chinese wormwood (Artemisia absinthium – Figure 3), tur-
meric (Curcuma longa – Figure 4) and Scutellaria Baicalensis
are commonly employed by traditional practitioners and
studies demonstrate that their actions are at least in-part
achieved by blocking the critical process of tumour vascu-
larisation [51]. In order for cancer cells to grow and
develop a healthy network of blood vessels high sources
of nutrients and oxygen are vital. The rapidly dividing
cells are subject to a hypoxic environment, so failure to
set-up this fundamental framework results in stunted
growth of the tumour (≤ 1–2 mm) and development of
necrosis at its core [52,53]. Starving an established
tumour of its blood supply involves an intervention in the
complex angiogenic cascade, of which vascular endothe-
lial growth factor (VEGF) is the most reported biomarker
[54]. VEGF production is considered essential for angio-
genesis and cancer metastasis, with high titres being indic-
ative of a poor prognosis [55]. A wide array of oncogenes
(e.g. ras, HER-2, p53 and C-jun) and growth factors (EGF,
TGF, IGF and PDGF) have been identified as up-regulat-
ing VEGF-mRNA and so TCM that inhibits their expres-
sion and production, respectively, are also considered
invaluable tools in cancer therapy.
Artemisinin, an active constituent of Chinese wormwood
(Artemisia absinthium – Figure 3) is a potent antimalarial,
however more recently it has been shown to possess anti-
angiogenic properties, acting by lowering both VEGF and
its receptor (VEGF-R2(in embryo), KDR(in humans) and
flk-1(in mice)) in tumour and endothelial cells in a dose-
dependent manner [56-59].
Phytochemicals have long been used as 'lead compounds'
to generate drugs with better pharmacokinetic profiles
and reduced toxicity in vivo. Artesunate (ART) and dihy-
dro-ART are semi-synthetic derivatives of artemisinin with
demonstrable activity against a wide range of cancer cell
lines including KML-562 (chronic myeloid leukaemia),
HeLa (cervical cancer) and HO-8910 (ovarian cancer)
[60-62]. Human umbilical vein endothelial cells
(HUVECs) are commonly employed alongside cancer cell
assays to assess the extent to which angiogenesis is
induced by way of new micro-vessel tube formation. Stud-
ies using this model show that dihydro-ART has signifi-
cant anti-angiogenic activity compared to ART and
prevents new-microvessel formation by 70–90% in vitro
[61]. Along with the low toxicity profile associated with
these agents their future role to complement treatment
regimes is encouraging and warrants further investigation.
Curcumin (Curcuma longa – Figure 4), the principle curcu-
minoid in turmeric and widely used culinary spice is cyto-
toxic to cancer cells on a number of levels with a proven
synergy when used in combination with chemotherapy/
radiotherapy [63-65]. Its angioinhibitory action has been
substantiated in a number of cancer cell lines including
that of the breast where it was found to inhibit two major
angiogenic factors, VEGF and b-FGF (basic-fibroblast
growth factor) [66,67]. Besides this it also impedes
tumour cell invasion, a property found to diminish circu-
lating but not established metastases. It does this via
downregulation of matrix metalloproteinases (MMP),
most notably MMP-2 & MMP-9 – responsible for the inva-
sive growth property of tumours [68-70]. In Ehrlich
ascites tumour (EAT) cells a time-dependent inhibition of
VEGF and key growth factor angiopoietin was observed,
combined with an anti-proliferative effect on HUVECs,
this being attributed directly to VEGF and NF-κB inhibi-
tion [71,72]. Other reported actions of curcumin include
inhibition of epidermal growth factor receptor (EGFR)
and intracellular signalling tyrosine kinases, the latter of
which are known to promote angiogenesis through gene
activation of cyclooxygenase-2, IL-2 and MMPs [73-75].
Derivatives of curcumin have also being investigated with
preliminary findings pointing towards an increase in anti-
tumor activity, although further corroborative studies are
necessary to confirm these findings [76-78].
Plant of Artemisia absinthium ('Chinese wormwood') Figure 3
Plant of Artemisia absinthium ('Chinese wormwood').Molecular Cancer 2009, 8:21 http://www.molecular-cancer.com/content/8/1/21
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TCM often possess quite distinct and specialised modes of
action, and consequently tumours normally resistant to
conventional chemotherapy are reported to be more sus-
ceptible to TCM therapy [79]. They have demonstrable
and often direct inhibitory effects on tumour cell growth
and proliferation, affecting different stages of the cell
growth cycle and mitotic phase [80]. Herbal compounds
such as paclitaxel (Taxol®) and its derivatives suppress
microtubule depolymerization, thus terminating cell
mitosis [81]. As a result these, and compounds including
harringtonine (Cephalotaxus hainanensis) and camp-
tothecin (Camptotheca acuminata) with similar mecha-
nisms of action are already commonly used in the clinic
as anticancer agents for a variety of cancers [82]. The
mechanism of action of camptothecin (Camptotheca acu-
minata) being to inhibit DNA topoisomerase I, conse-
quently affecting DNA replication; paclitaxel is a mitotic
spindle inhibitor (spindle poison), which can also bind
with tubulin and prevent the normal physiological proc-
ess of microtubule depolymerization.
Anticancer properties of the TCM elemene (Rhizoma
Zedoariae) and oridonin (Rabdosia rubescens) lend them-
selves to being co-administered with conventional chem-
otherapeutic agents (e.g. doxorubicin and 5-fluorouracil
(5-FU)) to impart a synergistic anti-tumour effect. Com-
bining elemene (Rhizoma Zedoariae) with the pyrimidine
base analogue 5-FU, resulted in significantly higher
tumour growth inhibitive effects [83]. The anti-tumour
activity of another TCM, 'half-flag' (Pteris semipinnata L. –
Figure 5) was also significant, being shown to inhibit
DNA production in HL-60 cells by 41% when combined
with 5-FU, compared to only 10% in cells treated with the
TCM alone. Half-flag also improved the anticancer effi-
ciency of several other chemotherapeutic drugs when used
concomitantly [84].
Similarly, derivatives of the herbal compound berbamine
(Berberis amurensis), namely EBB (O-(4-ethoxyl-butyl)-
berbamine) when combined with cyclophosphamide and
mitomycin-C respectively enhanced the antitumor capac-
ity, while also significantly improving patients' quality of
life [85]. Zhang and co-workers tested 20 natural flavo-
noid compounds in breast cancer cell lines discovering
they assist in the intracellular accumulation of anthracy-
cline drugs while also reversing anthracene resistance
[86,87]. Kim SW et al., reported that ginsenoside-Rg3
(Panax ginsenoside Rg3) promotes Rhodamine-123 accu-
mulation in vincristine-resistant KBV20C human fibrob-
last cancer cells, reversing vincristine resistance acquired
by a variety of cells [88].
The discovery that single components within TCM have
the potential to overcome multidrug resistance developed
by tumour cells opens the door to new avenues of multi-
drug/TCM therapy. These findings justify and moreover
pave the way for them to be used alongside conventional
drugs, where significant resistance to therapy has already
developed.
Plant (A) and root (B) of Curcuma longa ('curcumin') where root scale is shown as 1 cm Figure 4
Plant (A) and root (B) of Curcuma longa ('curcumin') where root scale is shown as 1 cm.
A BMolecular Cancer 2009, 8:21 http://www.molecular-cancer.com/content/8/1/21
Page 6 of 8
(page number not for citation purposes)
Although only one clinical trial using TCM was reported
up until 2001 it was poorly controlled and any conclu-
sions drawn were deemed unreliable, it is noteworthy
however that given the very recent attention being
received by TCM a re-analysis study has since been con-
ducted [89,90]. This raises the call for more well-defined,
robust and regulated clinical trials on TCM to ensure reli-
able data is generated which would enable regulatory
authorities and clinicians alike to make well-informed
decisions when considering their incorporation into west-
ern formularies.
Conclusion
In treating diseases/illnesses of a systemic nature the typi-
cal route of TCM administration is oral. This is deemed a
far from optimal approach in cancer patients given
patient-to-patient variability when formulating TCM, the
unpredictable absorption profile of the various bioactives
across the gastrointestinal tract together with compliance
issues. Furthermore, the challenge of ensuring batch-to-
batch reproducibility of any given formulation remains,
although the adoption of cutting-edge genetic/chemical
fingerprinting in conjunction with micro-array-based cell
line testing offers unique solutions to this. With modern
techniques of isolation, characterisation and functionali-
sation of compounds along with in vitro/in vivo testing
now common place within research facilities where drug
discovery and delivery is a focus, the drive to engineer
well-defined, targeted drug delivery systems offers a new
dawn for this very traditional practice of medicine [91-
93]. By identifying potent bioactives derived from TCM as
discussed above, and tailoring formulations that encapsu-
late/incorporate them into cutting-edge drug delivery sys-
tems for parenteral administration one can envision
overcoming the shortfalls that have prevented TCM being
accepted by the West as a real adjunct/alternative to con-
ventional cancer therapies. With a library of over 250,000
individual therapeutic compounds at our disposal, many
of which have yet to be successfully isolated and tested for
both safety and efficacy, there are certainly challenges that
lay ahead – the scope and scale of which could well revo-
lutionise drug discovery and delivery in the fight against
cancer, for many decades to come.
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